Literature DB >> 17195422

Minimal change disease: a review.

Tapasi C Saha1, Harmeet Singh.   

Abstract

Minimal change disease (MCD) is a histopathological lesion in the kidney that is most commonly associated with nephrotic syndrome. The majority of the cases are idiopathic. Pathogenesis is not well understood, although T-cell-related mechanisms are implicated. Massive proteinuria leads to hypoalbuminemia, salt retention, disorder of hemostasis, hyperlipidemia and increased susceptibility to infections. Renal biopsy remains the gold standard for diagnosis. MCD is highly responsive to corticosteroids. Other immunosuppressive agents such as cyclophosphamide, cyclosporin, azathioprine and mycophenolate mofetil have been used to treat cases which are resistant to steroids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195422     DOI: 10.1097/01.smj.0000243183.87381.c2

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

1.  LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile.

Authors:  Tarak Srivastava; Mukut Sharma; Kok-Hooi Yew; Ram Sharma; R Scott Duncan; Moin A Saleem; Ellen T McCarthy; Alexander Kats; Patricia A Cudmore; Uri S Alon; Christopher J Harrison
Journal:  J Cell Commun Signal       Date:  2012-11-17       Impact factor: 5.782

2.  Genes unlinked to the leptin receptor influence urinary albumin excretion in obese Zucker rats.

Authors:  Kyoungmi Kim; Craig H Warden; Stephen M Griffey; Jose G Vilches-Moure; Susan Hansen; Edwin Cuppen; Isaäc J Nijman; Sally Chiu; Judith S Stern
Journal:  Physiol Genomics       Date:  2010-02-16       Impact factor: 3.107

3.  Study on Steroid Induced Ocular Findings in Children with Nephrotic Syndrome.

Authors:  Vijay Agrawal; Kusum Devpura; Laxmikant Mishra; Sajan Agarwal
Journal:  J Clin Diagn Res       Date:  2017-03-01

4.  A case of minimal change disease in a Fabry patient.

Authors:  Yuri A Zarate; Larry Patterson; Hong Yin; Robert J Hopkin
Journal:  Pediatr Nephrol       Date:  2009-10-30       Impact factor: 3.714

5.  Clinical outcomes and predictors for ESRD and mortality in primary GN.

Authors:  Yu-Hsiang Chou; Yu-Chung Lien; Fu-Chang Hu; Wei-Chou Lin; Chih-Chin Kao; Chun-Fu Lai; Wen-Chih Chiang; Shuei-Liong Lin; Tun-Jun Tsai; Kwan-Dun Wu; Yung-Ming Chen
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 8.237

6.  Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine.

Authors:  Belinda Galeano; Riko Klootwijk; Irini Manoli; MaoSen Sun; Carla Ciccone; Daniel Darvish; Matthew F Starost; Patricia M Zerfas; Victoria J Hoffmann; Shelley Hoogstraten-Miller; Donna M Krasnewich; William A Gahl; Marjan Huizing
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

7.  A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.

Authors:  Marinus J Dekkers; Jaap W Groothoff; Robert Zietse; Michiel G H Betjes
Journal:  BMC Res Notes       Date:  2015-06-26

8.  A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis.

Authors:  Michael Boehm; Eva Nora Bukosza; Nicole Huttary; Rebecca Herzog; Christoph Aufricht; Klaus Kratochwill; Christoph A Gebeshuber
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

9.  Medullary nephrocalcinosis, distal renal tubular acidosis and polycythaemia in a patient with nephrotic syndrome.

Authors:  Suneth Karunarathne; Yapa Udayakumara; Dumitha Govindapala; Harshini Fernando
Journal:  BMC Nephrol       Date:  2012-07-26       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.